Cargando…

Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients

BACKGROUND: Imatinib reduced 90-day mortality in hospitalised coronavirus disease 2019 (COVID-19) patients in a recent clinical trial, but the biological effects that cause improved clinical outcomes are unknown. We aimed to determine the biological changes elicited by imatinib in patients with COVI...

Descripción completa

Detalles Bibliográficos
Autores principales: de Brabander, Justin, Duijvelaar, Erik, Schippers, Job R., Smeele, Patrick J., Peters-Sengers, Hessel, Duitman, Jan Willem, Aman, Jurjan, Bogaard, Harm Jan, van der Poll, Tom, Bos, Lieuwe D.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301934/
https://www.ncbi.nlm.nih.gov/pubmed/35896211
http://dx.doi.org/10.1183/13993003.00780-2022